Ra Eeles

List of Publications by Year in Descending Order

178 papers	18,522 citations	66 h-index	135 g-index
202 ext. papers	23,117 ext. citations	10.9 avg, IF	5.53 L-index

#	Paper	IF	Citations
178	Genetics of prostate cancer and its utility in treatment and screening. *Advances in Genetics*, **2021**, 108, 147-199	3.3	0
177	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. *Lancet Oncology, The*, **2021**, 22, 1618-1631	21.7	10
176	Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk. *Current Genetic Medicine Reports*, **2021**, 9, 47-58	2.2	2
175	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. *Scientific Reports*, **2021**, 11, 9264	4.9	3
174	Oncologically Relevant Findings Reporting and Data System (ONCO-RADS): Guidelines for the Acquisition, Interpretation, and Reporting of Whole-Body MRI for Cancer Screening. *Radiology*, **2021**, 299, 494-507	20.5	4
173	Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium. *European Journal of Epidemiology*, **2021**, 36, 913-925	12.1	2
172	Two-stage Study of Familial Prostate Cancer by Whole-exome Sequencing and Custom Capture Identifies 10 Novel Genes Associated with the Risk of Prostate Cancer. *European Urology*, **2021**, 79, 353-361	10.2	9
171	FRMD6 has tumor suppressor functions in prostate cancer. *Oncogene*, **2021**, 40, 763-776	9.2	11
170	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer. *International Journal of Cancer*, **2021**, 148, 99-105	7.5	7
169	Genetic predisposition to prostate cancer: an update. *Familial Cancer*, **2021**, 1	3	6
168	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. *Nature Genetics*, **2021**, 53, 65-75	36.3	62
167	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2021**, 24, 532-541	6.2	3
166	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. *Nature Communications*, **2021**, 12, 1236	17.4	14
165	Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. *Journal of Pathology: Clinical Research*, **2021**, 7, 311-325	5.3	6
164	Identification of Germline Genetic Variants that Increase Prostate Cancer Risk and Influence Development of Aggressive Disease. *Cancers*, **2021**, 13,	6.6	8
163	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
162	Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk. *European Urology*, **2021**, 80, 134-138	10.2	7

161	Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. *European Urology Oncology*, **2021**, 4, 570-579	6.7	12
160	The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. *BJU International*, **2021**,	5.6	4
159	Prostate cancer risk in men of differing genetic ancestry and approaches to disease screening and management in these groups.. *British Journal of Cancer*, **2021**,	8.7	1
158	The Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. *Cancers*, **2020**, 12,	6.6	4
157	A Germline Variant at 8q24 Contributes to Familial Clustering of Prostate Cancer in Men of African Ancestry. *European Urology*, **2020**, 78, 316-320	10.2	13
156	The effect of sample size on polygenic hazard models for prostate cancer. *European Journal of Human Genetics*, **2020**, 28, 1467-1475	5.3	5
155	Prostate Cancer Risk by BRCA2 Genomic Regions. *European Urology*, **2020**, 78, 494-497	10.2	2
154	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1731-1738	4	14
153	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
152	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *European Urology*, **2020**, 77, 508-547	10.2	155
151	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
150	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. *European Urology*, **2020**, 77, 24-35	10.2	53
149	Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. *Prostate Cancer and Prostatic Diseases*, **2020**, 23, 333-342	6.2	5
148	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. *Nature Communications*, **2020**, 11, 3905	17.4	12
147	Radiogenomics Consortium Genome-Wide Association Study Meta-Analysis of Late Toxicity After Prostate Cancer Radiotherapy. *Journal of the National Cancer Institute*, **2020**, 112, 179-190	9.7	32
146	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. *European Urology*, **2019**, 76, 831-842	10.2	78
145	Patterns of recurrence after prostate bed radiotherapy. *Radiotherapy and Oncology*, **2019**, 141, 174-180	5.3	10
144	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45

143	Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in Over 140,000 European Descendants. *Cancer Research*, **2019**, 79, 3192-3204	10.1	23
142	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. *Nature Communications*, **2019**, 10, 2154	17.4	81
141	Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations. *BJU International*, **2019**, 123, 284-292	5.6	7
140	Runs of homozygosity and testicular cancer risk. *Andrology*, **2019**, 7, 555-564	4.2	3
139	Analysis of Over 140,000 European Descendants Identifies Genetically Predicted Blood Protein Biomarkers Associated with Prostate Cancer Risk. *Cancer Research*, **2019**, 79, 4592-4598	10.1	9
138	Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel. *European Urology*, **2019**, 76, 329-337	10.2	28
137	Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study. *PLoS Medicine*, **2019**, 16, e1002998	11.6	29
136	Homeobox B13 G84E Mutation and Prostate Cancer Risk. *European Urology*, **2019**, 75, 834-845	10.2	16
135	Circulating vitamin D concentrations and risk of breast and prostate cancer: a Mendelian randomization study. *International Journal of Epidemiology*, **2019**, 48, 1416-1424	7.8	24
134	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. *Nature Genetics*, **2018**, 50, 682-692	36.3	112
133	Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. *Nature Communications*, **2018**, 9, 1340	17.4	39
132	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
131	Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. *Prostate Cancer and Prostatic Diseases*, **2018**, 21, 228-237	6.2	7
130	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. *BMJ, The*, **2018**, 360, j5757	5.9	85
129	DESNT: A Poor Prognosis Category of Human Prostate Cancer. *European Urology Focus*, **2018**, 4, 842-850	5.1	18
128	Rare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease. *British Journal of Cancer*, **2018**, 119, 96-104	8.7	27
127	A Review of Prostate Cancer Genome-Wide Association Studies (GWAS). *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 845-857	4	73
126	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. *Nature Genetics*, **2018**, 50, 928-936	36.3	340

125	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. *Nature Communications*, **2018**, 9, 2256	17.4	57
124	Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. *Oncotarget*, **2018**, 9, 12630-12638	5.5	6
123	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 58-66	4	2
122	Men with a susceptibility to prostate cancer and the role of genetic based screening. *Translational Andrology and Urology*, **2018**, 7, 61-69	2.3	14
121	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. *Nature Communications*, **2018**, 9, 4616	17.4	30
120	Large-scale transcriptome-wide association study identifies new prostate cancer risk regions. *Nature Communications*, **2018**, 9, 4079	17.4	65
119	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. *Nature Communications*, **2018**, 9, 3707	17.4	57
118	Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. *Blood*, **2018**, 132, 2040-2052	2.2	10
117	Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. *European Urology*, **2018**, 74, 248-252	10.2	13
116	Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. *Familial Cancer*, **2017**, 16, 433-440	3	39
115	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA - Journal of the American Medical Association*, **2017**, 317, 2402-2416	27.4	1140
114	Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. *Nature Genetics*, **2017**, 49, 1133-1140	36.3	89
113	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
112	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
111	Appraising the relevance of DNA copy number loss and gain in prostate cancer using whole genome DNA sequence data. *PLoS Genetics*, **2017**, 13, e1007001	6	20
110	Ambiguity in a masculine world: Being a BRCA1/2 mutation carrier and a man with prostate cancer. *Psycho-Oncology*, **2017**, 26, 1987-1993	3.9	9
109	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. *British Journal of Cancer*, **2017**, 117, 734-743	8.7	5
108	Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis. *JAMA Oncology*, **2017**, 3, 1634-1639	13.4	107

107	Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. *Nature Communications*, **2017**, 8, 1892	17.4	24
106	Quantifying the Genetic Correlation between Multiple Cancer Types. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1427-1435	4	25
105	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 126-135	4	183
104	Two Novel Susceptibility Loci for Prostate Cancer in Men of African Ancestry. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	38
103	seXY: a tool for sex inference from genotype arrays. *Bioinformatics*, **2017**, 33, 561-563	7.2	3
102	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
101	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. *Nature Communications*, **2016**, 7, 10979	17.4	37
100	Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21. *Human Genetics*, **2016**, 135, 923-38	6.3	27
99	LocusExplorer: a user-friendly tool for integrated visualization of human genetic association data and biological annotations. *Bioinformatics*, **2016**, 32, 949-51	7.2	10
98	A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2016**, 25, 193-200	4	47
97	Prostate cancer genome-wide association study from 89,000 men using the OncoArray chip to identify novel prostate cancer susceptibility loci.. *Journal of Clinical Oncology*, **2016**, 34, 1525-1525	2.2	4
96	A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population. *Oncotarget*, **2016**, 7, 21393-403	3.3	17
95	Post hoc Analysis for Detecting Individual Rare Variant Risk Associations Using Probit Regression Bayesian Variable Selection Methods in Case-Control Sequencing Studies. *Genetic Epidemiology*, **2016**, 40, 461-9	2.6	3
94	Germline genetic profiling in prostate cancer: latest developments and potential clinical applications. *Future Science OA*, **2016**, 2, FSO87	2.7	10
93	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 443-53	59.2	791
92	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
91	Diagnosis and Management of Hereditary Carcinoids. *Recent Results in Cancer Research*, **2016**, 205, 149-68	2.5	6
90	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. *Oncologist*, **2016**, 21, 716-22	5.7	24

89	Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. *Cancer Research*, **2016**, 76, 5103-14	10.1	66
88	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
87	REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. *American Journal of Human Genetics*, **2016**, 99, 877-885	11	722
86	Prevalence of the HOXB13 G84E germline mutation in British men and correlation with prostate cancer risk, tumour characteristics and clinical outcomes. *Annals of Oncology*, **2015**, 26, 756-761	10.3	67
85	The role of the prostate cancer gene 3 urine test in addition to serum prostate-specific antigen level in prostate cancer screening among breast cancer, early-onset gene mutation carriers. *Urologic Oncology: Seminars and Original Investigations*, **2015**, 33, 202.e19-28	2.8	7
84	Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. *Human Molecular Genetics*, **2015**, 24, 5603-18	5.6	35
83	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1121-9	4	46
82	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
81	Multi-stage genome-wide association study identifies new susceptibility locus for testicular germ cell tumour on chromosome 3q25. *Human Molecular Genetics*, **2015**, 24, 1169-76	5.6	26
80	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. *Genome Research*, **2015**, 25, 814-24	9.7	52
79	Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue. *Nature Genetics*, **2015**, 47, 367-372	36.3	292
78	The evolutionary history of lethal metastatic prostate cancer. *Nature*, **2015**, 520, 353-357	50.4	857
77	Adjuvant Hormone Therapy May Improve Survival in Epithelial Ovarian Cancer: Results of the AHT Randomized Trial. *Journal of Clinical Oncology*, **2015**, 33, 4138-44	2.2	78
76	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. *Human Molecular Genetics*, **2015**, 24, 5589-602	5.6	54
75	Identification of four new susceptibility loci for testicular germ cell tumour. *Nature Communications* , **2015**, 6, 8690	17.4	30
74	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. *New England Journal of Medicine*, **2015**, 373, 1697-708	59.2	1345
73	Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. *Human Molecular Genetics*, **2015**, 24, 7406-20	5.6	11
72	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. *British Journal of Cancer*, **2015**, 113, 1086-93	8.7	21

71	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. *Genetics in Medicine*, **2015**, 17, 789-95	8.1	70
70	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. *European Urology*, **2015**, 68, 186-93	10.2	192
69	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
68	The psychological impact of undergoing genetic-risk profiling in men with a family history of prostate cancer. *Psycho-Oncology*, **2015**, 24, 1492-9	3.9	17
67	Spatial genomic heterogeneity within localized, multifocal prostate cancer. *Nature Genetics*, **2015**, 47, 736-45	36.3	306
66	Generalizability of established prostate cancer risk variants in men of African ancestry. *International Journal of Cancer*, **2015**, 136, 1210-7	7.5	51
65	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *European Urology*, **2014**, 66, 489-99	10.2	156
64	Li-Fraumeni syndrome: cancer risk assessment and clinical management. *Nature Reviews Clinical Oncology*, **2014**, 11, 260-71	19.4	162
63	The genetic epidemiology of prostate cancer and its clinical implications. *Nature Reviews Urology*, **2014**, 11, 18-31	5.5	162
62	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. *Nature Genetics*, **2014**, 46, 1103-9	36.3	331
61	Prevention and early detection of prostate cancer. *Lancet Oncology, The*, **2014**, 15, e484-92	21.7	277
60	Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. *Lancet Oncology, The*, **2014**, 15, 1521-1532	21.7	218
59	Frequent germline deleterious mutations in DNA repair genes in familial prostate cancer cases are associated with advanced disease. *British Journal of Cancer*, **2014**, 110, 1663-72	8.7	83
58	Comprehensive functional annotation of 77 prostate cancer risk loci. *PLoS Genetics*, **2014**, 10, e1004102	6	132
57	Fine-mapping the HOXB region detects common variants tagging a rare coding allele: evidence for synthetic association in prostate cancer. *PLoS Genetics*, **2014**, 10, e1004129	6	30
56	Diffusion-weighted MRI for detecting prostate tumour in men at increased genetic risk. *European Journal of Radiology Open*, **2014**, 1, 22-27	2.6	6
55	"It's all very well reading the letters in the genome, but it's a long way to being able to write": Men's interpretations of undergoing genetic profiling to determine future risk of prostate cancer. *Familial Cancer*, **2014**, 13, 625-35	3	14
54	Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. *Future Oncology*, **2014**, 10, 1679-94	3.6	7

53	Baseline and post prophylactic tubal-ovarian surgery CA125 levels in BRCA1 and BRCA2 mutation carriers. *Familial Cancer*, **2014**, 13, 197-203	3	2
52	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *Journal of Clinical Oncology*, **2013**, 31, 1748-57	2.2	440
51	Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis. *BJU International*, **2013**, 111, 1148-55	5.6	7
50	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nature Genetics*, **2013**, 45, 385-91, 391e1-2	36.3	413
49	Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14. *Nature Genetics*, **2013**, 45, 686-9	36.3	128
48	A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. *Human Molecular Genetics*, **2013**, 22, 408-15	5.6	109
47	Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. *Human Molecular Genetics*, **2013**, 22, 2520-8	5.6	88
46	Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. *Prostate Cancer*, **2013**, 2013, 560857	1.9	136
45	Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort. *BJU International*, **2013**, 112, 666-73	5.6	28
44	The role of BRCA1 and BRCA2 in prostate cancer. *Asian Journal of Andrology*, **2012**, 14, 409-14	2.8	85
43	Evaluating genetic risk for prostate cancer among Japanese and Latinos. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 2048-58	4	46
42	Germline BRCA1 mutations increase prostate cancer risk. *British Journal of Cancer*, **2012**, 106, 1697-701	8.7	203
41	Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. *BJU International*, **2011**, 107, 28-39	5.6	76
40	Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. *British Journal of Cancer*, **2011**, 104, 1656-63	8.7	127
39	Multicentric breast cancer: clonality and prognostic studies. *Breast Cancer Research and Treatment*, **2011**, 129, 703-16	4.4	12
38	BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. *British Journal of Cancer*, **2011**, 105, 1230-4	8.7	249
37	The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. *PLoS ONE*, **2010**, 5, e13363	3.7	68
36	Germ-line mutations in mismatch repair genes associated with prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 2460-7	4	84

35	Genetic testing for BRCA1: effects of a randomised study of knowledge provision on interest in testing and long term test uptake; implications for the NICE guidelines. *Familial Cancer*, **2009**, 8, 5-13	3	6
34	Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. *Nature Genetics*, **2009**, 41, 1116-21	36.3	360
33	Multiple loci on 8q24 associated with prostate cancer susceptibility. *Nature Genetics*, **2009**, 41, 1058-60	36.3	252
32	Multiple newly identified loci associated with prostate cancer susceptibility. *Nature Genetics*, **2008**, 40, 316-21	36.3	722
31	SNPs in the kallikrein gene region associated with prostate cancer risk: true cause or association by design?. *Nature Genetics*, **2008**, 40,	36.3	29
30	Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2008**, 17, 2052-61	4	134
29	Delivery of cancer genetics services: The Royal Marsden telephone clinic model. *Familial Cancer*, **2007**, 6, 213-9	3	10
28	Delivering cancer genetics services--new ways of working. *Familial Cancer*, **2007**, 6, 163-7	3	14
27	Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation. *Cancer Research*, **2006**, 66, 8966-70	10.1	37
26	Guilt, blame and responsibility: men understanding of their role in the transmission of BRCA1/2 mutations within their family. *Sociology of Health and Illness*, **2006**, 28, 969-88	3	65
25	Communication about genetic testing in families of male BRCA1/2 carriers and non-carriers: patterns, priorities and problems. *Clinical Genetics*, **2005**, 67, 492-502	4	91
24	Too much, too soon? Patients and health professionals views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40. *European Journal of Cancer Care*, **2005**, 14, 272-81	2.4	67
23	Men decision-making about predictive BRCA1/2 testing: the role of family. *Journal of Genetic Counseling*, **2005**, 14, 207-17	2.5	63
22	Juggling roles and expectations: dilemmas faced by women talking to relatives about cancer and genetic testing. *Psychology and Health*, **2004**, 19, 439-455	2.9	146
21	Unravelling the genetics of prostate cancer. *American Journal of Medical Genetics Part A*, **2004**, 129C, 65-73		52
20	The clinical genetics of prostate cancer. *Hereditary Cancer in Clinical Practice*, **2004**, 2, 111-21	2.3	5
19	P386: Screening for endometrial cancer in a high-risk population (Hereditary Non Polyposis Colorectal Cancer) pilot study. *Ultrasound in Obstetrics and Gynecology*, **2003**, 22, 174-174	5.8	
18	Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer. *Prostate Cancer and Prostatic Diseases*, **2003**, 6, 12-4	6.2	7

17	Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. *American Journal of Human Genetics*, **2003**, 72, 1-12	11	293
16	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. *Nature Genetics*, **2002**, 31, 55-9	36.3	863
15	Predictive testing for BRCA1/2: attributes, risk perception and management in a multi-centre clinical cohort. *British Journal of Cancer*, **2002**, 86, 1209-16	8.7	163
14	The genetics of breast cancer. *The Journal of the British Menopause Society*, **2002**, 8, 24-29		
13	An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations-fluorescent mutation detection (F-MD). *Human Mutation*, **2001**, 17, 220-32	4.7	14
12	Genetic predisposition to prostate cancer. *Prostate Cancer and Prostatic Diseases*, **1999**, 2, 9-15	6.2	50
11	Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. *International Journal of Cancer*, **1999**, 84, 458-65	7.5	100
10	Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study Collaborators. *International Journal of Cancer*, **1998**, 78, 1-7	7.5	27
9	Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. *Genes Chromosomes and Cancer*, **1998**, 21, 61-9	5	71
8	Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. *Human Molecular Genetics*, **1998**, 7, 507-15	5.6	458
7	Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer **1998**, 78, 1		1
6	Detection of point mutations in the p53 gene: comparison of single-strand conformation polymorphism, constant denaturant gel electrophoresis, and hydroxylamine and osmium tetroxide techniques. *Human Mutation*, **1993**, 2, 58-66	4.7	92
5	Head and neck sarcomas: prognostic factors and implications for treatment. *British Journal of Cancer*, **1993**, 68, 201-7	8.7	145
4	A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. *Nature Genetics*, **1992**, 2, 132-4	36.3	215
3	Non-Hodgkin© lymphoma presenting with extradural spinal cord compression: functional outcome and survival. *British Journal of Cancer*, **1991**, 63, 126-9	8.7	50
2	African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer		1
1	Assessment of Polygenic Architecture and Risk Prediction based on Common Variants Across Fourteen Cancers		1